Skip to content

Interventional Glaucoma Challenging the current standard of care

IOP-lowering drops can lead to a flood of issues

  • An icon of an eye with two horizontal arrows pointing inward towards the iris.

    Disease progression

    • Over 6 years, 4.7% of patients with primary open-angle glaucoma (POAG) went blind in at least 1 eye1,*
  • An icon of a desk with clock and bottle on top of it.

    Impact on patient quality of life and adherence

    • Chronic side effects, including hyperemia, periorbital fat atrophy, ocular surface disease (OSD), and hyperchromia2,3
      • 74% of patients with glaucoma using drops for at least 6 months had OSD4
    • Complex dosing regimens, instillation difficulties, inconvenience, and out-of-pocket costs5,6
    • >90% of patients were nonadherent with their IOP-lowering drops7
    • ~50% of patients stopped taking their IOP-lowering drops within 6 months7
  • An icon of a cycle of a stack of files, a clock, and a ringing telephone receiver.

    Practice management challenges

    • Administrative headaches, practice inefficiencies, pharmacy callbacks, patient callbacks, and wasted chair time

*A retrospective review of 149,172 patients from the IRIS® Registry with a diagnosis of POAG (7.2% mild, 5.1% moderate, 2.7% severe, 84.9% unspecified severity) and with repeat VA measurements over the period from 2014 to 2019. Incident blindness was defined as VA ≤20/200 in one or both eyes. Information regarding treatments received in this cohort was not provided; however, in another study of a cohort of POAG or glaucoma-suspect patients from the IRIS registry (263,480 eyes; 18.6% glaucoma suspect, 81.4% glaucoma [17.9% mild, 22.4% moderate, 13.9% severe, 45.7% unspecified severity]) followed from 2013 to 2018 who ultimately underwent LTP, the mean number of IOP-lowering medications used prior to LTP was 2.1.1,8

IOP=intraocular pressure; LTP=laser trabeculoplasty; VA=visual acuity.

Interventional glaucoma can help turn the tide

IG is a mindset9,10

  • Proactive vs reactive
  • Early procedural intervention
  • Early predictive diagnostics
  • Address adherence and risk
  • Active monitoring

A critical component of IG is a long-duration procedural pharmaceutical—a unique technology that delivers continuous prostaglandin analog therapy.11

IG=interventional glaucoma.

24/7

patient adherence through sustained drug elution5

HELPS
REDUCE

the flood of issues caused by drops2,5-7

DISCOVER iDOSE TR

Ready to hear more?

Contact a representative to request more info.

References: 1. Williams AM, Liang HW, Lin HS. Lost to follow-up and risk of incident blindness among patients with glaucoma in the IRIS® Registry. Ophthalmol Glaucoma. 2025:S2589-4196(25)00104-8. 2. Teymoorian S, Kaur J. Travoprost intracameral implant in eyes with glaucoma or ocular hypertension: early short-term real-world outcomes. Clin Ophthalmol. 2025;19:157-166. 3. Detry-Morel M. Side effects of glaucoma medications. Bull Soc Belge Ophtalmol. 2006;(299):27-40. 4. Chaneker SN, Usgaonkar UP, Akarkar SO. Ocular surface disease in glaucoma patients on topical medications and its relation to duration of treatment and number of medications. Journal of Clinical Ophthalmology and Research. 2022;10(2):55-58. 5. Berdahl JP, Sarkisian SR Jr, Ang RE, et al. Efficacy and safety of the travoprost intraocular implant in reducing topical IOP-lowering medication burden in patients with open-angle glaucoma or ocular hypertension. Drugs. 2024;84(1):83-97. 6. Economic burden worsens for glaucoma patients. Review of Optometry. Published March 24, 2021. Accessed August 7, 2025. https://www.reviewofoptometry.com/article/economic-burden-worsens-for-glaucoma-patients 7. Nordstrom BL, Friedman DS, Mozaffair E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140(4):598-606. 8. Chang TC, Parrish RK, Fujino D, Kelly SP, Vanner EA. Factors associated with favorable laser trabeculoplasty response: IRIS registry analysis. Am J Ophthalmol. 2021;223:149-158. 9. Bacharach J, Blieden LS, Chaya C, et al. What does interventional glaucoma mean to you? Glaucoma Today. 2020:40-43. 10. Balas M, Mathew DJ. Minimally invasive glaucoma surgery: a review of the literature. Vision (Basel). 2023;7(3):54. 11. iDose TR (travoprost intracameral implant) 75 mcg Prescribing Information. Glaukos Corporation. 2023.

Important Safety Information

Dosage and Administration

For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions.

Contraindications

iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch’s Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.

Warnings and Precautions

iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.

Adverse Reactions

In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity.

Indications and Usage

iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Please see full Prescribing Information.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.

The information contained in this site is intended for US healthcare professionals only.

YES, I AM A US HEALTHCARE PROFESSIONAL NO, I AM NOT A US HEALTHCARE PROFESSIONAL

Request more info

"*" indicates required fields

*Required.

By entering this information, you confirm that you are at least 18 years old and that you have read and accept the terms of our Privacy Policy. Glaukos will use the information you provide on this form to provide product updates and other promotional materials. Should you change your mind, you may unsubscribe using the link in the footer of any email you receive from us.

Stay connected

Sign up to receive the latest information about iDose® TR!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
*Required.

Glaukos will use the information you provide on this form to get in touch with you.

By entering this information, you confirm that you are at least 18 years old and that you have read and accept the terms of our Privacy Policy. Glaukos will use the information you provide on this form to provide product updates and other promotional materials. Should you change your mind, you may unsubscribe using the link in the footer of any email you receive from us.